Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Thymoma 1Squamous Cell Carcinoma of Head and Neck 1Oropharyngeal Neoplasms 1Neoplasms 1Mouth Neoplasms 1Head and Neck Neoplasms 1Endometrial Neoplasms 1Carcinoma, Lobular 1Breast Neoplasms 1

Interventions

Fulvestrant 64Paclitaxel 54Letrozole 54Trastuzumab 42pembrolizumab 41ribociclib 39palbociclib 35Capecitabine 35Specimen Handling 34Carboplatin 34Anastrozole 34exemestane 31abemaciclib 31Tamoxifen 31pertuzumab 29Cyclophosphamide 27Magnetic Resonance Spectroscopy 25trastuzumab deruxtecan 23Radiotherapy 21Surveys and Questionnaires 20Blood Specimen Collection 20olaparib 18Standard of Care 17Docetaxel 17Biopsy 17130-nm albumin-bound paclitaxel 15eribulin 14Taxes 14Methods 14Mastectomy, Segmental 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Breast Neoplasms × Radiotherapy, Adjuvant × 90 days × Clear all
NCT06897488 2026-05-15

EMERALD: Endocrine Therapy oMission With Radiation in ER+ Breast Cancer: Assessing Quality of Life and Disease Control: a Prospective Phase II Trial

M.D. Anderson Cancer Center

Phase 2 Recruiting
300 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡